Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial ...

In the first episode of the Ring Recipes series, a delicious flap jack sandwich comes to life on the 22" Blackstone griddle. Crispy, fluffy, and packed with flavor, this breakfast creation is pure ...

Interim University of Florida President Kent Fuchs's contract has been extended one month to Sept. 1. A new interim president will be named before Fuchs steps down, with a presidential search to begin ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

THE BRONX (WABC) -- It was a dream come true for two young brothers from Brooklyn who have muscular dystrophy. Carmine and Vincent Gagliano are huge Yankees fans, and on Thursday, their favorite team ...

Panelists discuss how recent advancements in muscular dystrophy treatment have evolved toward truly disease-modifying therapies using gene replacement, antisense oligonucleotides, and gene transfer ...

Fuchs SE is a highly profitable, niche-focused lubricant leader with strong pricing power, a net-cash balance sheet, and 23 years of consecutive dividend growth. The current market undervalues the ...

The prototype Gurney flap was developed on the 1971 Olsonite Eagle in advance of a USAC rule change that allowed detached wings for 1972. But for a twist of fate, the Gurney flap might well be known ...

Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage ...

Occurred on December 15, 2024 / London, UK Info from Licensor: "Alfie, our five month old kitten likes smacking cat flaps. Alfie thinks the cat flap is alive or that something alive behind the cat ...

Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire Kate Therapeutics, according to the Big Pharma’s CEO. The Swiss drugmaker ...